News

Home>News
News2020-07-17T11:41:26-04:00
Mar 142023

Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens

March 14th, 2023|Categories: Featured, Investor News, Medical, Press Releases|Tags: , , , , , |

Halberd’s patented process demonstrates eradication of multiple strains of antibiotic resistant bacteria and fungi in under 10 minutes. Jackson Center, PA, March 14, 2023 – Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd’s incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and Candida auris samples previously provided by the CDC. The testing, currently underway at Youngstown State University (YSU) using ...

Feb 212023

Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria

February 21st, 2023|Categories: Featured, Investor News, Medical, News, Press Releases|Tags: , , , , |

Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in-vitro Jackson Center, PA, February 21, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under ten minutes.  Halberd’s patented extracorporeal process and patent-pending laser eradication method in conjunction with metallic nanoparticles eliminated 99.5% of the bacteria from the sample. Dr. Cooper, Professor, Department ...

Feb 132023

Halberd Corporation Announces Breakthrough in Candida auris Treatment

February 13th, 2023|Categories: Investor News, Medical, News, Press Releases|Tags: , , , , , , |

Halberd Demonstrates Eradication of Candida Auris Fungus in as little as five minutes. Jackson Center, PA, February 13, 2023 – Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. ...

Feb 82023

Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria

February 8th, 2023|Categories: Investor News, Medical, News, Press Releases|Tags: , , , , , , , , , |

Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing Jackson Center, PA, February 8, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples.  Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria at Youngstown State University (YSU).  The research is being carried out by Dr. Chester Cooper and Dr. W. Gregg Sturrus ...

Jan 242023

Halberd Agrees to Animal Testing at Mississippi State University

January 24th, 2023|Categories: Investor News, Medical, News, Press Releases|Tags: , , |

College of Veterinary Medicine to conduct testing Jackson Center, PA January 24, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) has agreed to conduct animal testing at Mississippi State University’s (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working with Halberd Corporation on an upcoming research project.  The project will be investigating the effectiveness of novel therapeutic ...

Jan 32023

Halberd Corporation 2022 Year End CEO Letter and 2023 Goals

January 3rd, 2023|Categories: Featured, Investor News, Press Releases, Update Letter|Tags: , , , |

Profound Advancements Explained Jackson Center, PA, January 3, 2023 -- Halberd Corporation (OTC: HALB) The second half of 2022 was a very busy time. 2022 2nd HALF ACHIEVEMENTS Halberd’s previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%. Halberd formed a Cancer Therapeutics Subsidiary, Halberd Cancer Therapeutics, LTD, to allow cancer treatment research to continue in parallel and ...

Go to Top